Auxilium Pharmaceuticals (NASDAQ: AUXL) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Auxilium Pharmaceuticals and Biogen, as provided by MarketBeat.com.
Biogen has a consensus price target of $331.23, indicating a potential upside of 16.76%. Given Biogens higher probable upside, analysts plainly believe Biogen is more favorable than Auxilium Pharmaceuticals.
Institutional & Insider Ownership
88.4% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Auxilium Pharmaceuticals and Biogens net margins, return on equity and return on assets.
Valuation and Earnings
This table compares Auxilium Pharmaceuticals and Biogens top-line revenue, earnings per share (EPS) and valuation.
Biogen has higher revenue and earnings than Auxilium Pharmaceuticals.
Summary
Biogen beats Auxilium Pharmaceuticals on 9 of the 9 factors compared between the two stocks.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in mens healthcare. The companys products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Biogen Company Profile
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Companys product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
View original post here:
Auxilium Pharmaceuticals (NASDAQ:AUXL) & Biogen (BIIB) Financial Review - StockNewsTimes
